Clinical TopicsMedicationsNewsPrimary Care
UTI

FDA approves new treatment for UTIs

Author(s): By Dave Gilmartin
Share

The U.S. Food and Drug Administration (FDA) has approved a new treatment for uncomplicated urinary tract infections (uUTI).

Orlynvah oral tablets are taken twice a day for five days and are intended for use in uUTIs caused by certain bacteria (Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis) in women who have limited oral treatment options.

It is not indicated for treatment of complicated urinary tract infections, where clinical trials did not show effectiveness.

Two clinical trials did show Orlynvah’s effectiveness with women who had amoxicillin/clavulanate-susceptible pathogens and with ciprofloxacin-resistant pathogens.

The most common side effects were diarrhea, nausea, vaginal yeast infection, headache, and vomiting. 

Approximately half of all women will have at least one uUTI in her lifetime.

Get your free subscription to the Women's Healthcare Newsletter!

Women's Healthcare Newsletter Sidebar

Enter your email to receive our bi-weekly newsletter from the publishers of Women's Healthcare

  • This field is for validation purposes and should be left unchanged.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Quiz

According to the CDC, approximately how many women will develop breast cancer in their life?

Let Us Know What You Think

Poll